Peculiarities of the influenza and ARVI viruses circulation during epidemic season 2019–2020 in some regions of Russia

L'vov, D K; Burtseva, Elena; Колобухина, Л В; Fedyakina, I. Т.; Бовин, Н. В.; Ignatjeva, Anna V.; Krasnoslobodtsev, K. G.; Феодоритова, Е Л; Трушакова, С. В.; Breslav, N. V.; Merkulova, L. N.; Мукашева, Е. А.; Khlopova, I. N.; Voronina, Olga; Aksyonova, E. I.; Kunda, Marina S.; Рыжова, Н. Н.; Vartanjan, R. V.; Kistenyova, L. B.; Кириллов, И. М.; Прошина, Е С; Росаткевич, А. Г.; Kruzhkova, Irina; Zaplatnikov, A.L.; Базарова, М. В.; Smetanina, S.V.; Kharlamov, M. V.; Karpov, N. L.; Shikhin, A. V.

doi:10.36233/0507-4088-2020-65-6-4

Cited by 21 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunogenicity of prepared mRNAs were investigated in mice using HAI assay, as described previously ( 29 ). Initially, we tested the immunogenicity of H1 and H3 HA-encoding mRNAs separately ( Supplementary Figure S1 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Mazunina,

Gushchin,

Kleymenov

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Seasonal influenza remains a serious global health problem, leading to high mortality rates among the elderly and individuals with comorbidities. Vaccination is generally accepted as the most effective strategy for influenza prevention. While current influenza vaccines are effective, they still have limitations, including narrow specificity for certain serological variants, which may result in a mismatch between vaccine antigens and circulating strains. Additionally, the rapid variability of the virus poses challenges in providing extended protection beyond a single season. Therefore, mRNA technology is particularly promising for influenza prevention, as it enables the rapid development of multivalent vaccines and allows for quick updates of their antigenic composition. mRNA vaccines have already proven successful in preventing COVID-19 by eliciting rapid cellular and humoral immune responses. In this study, we present the development of a trivalent mRNA vaccine candidate, evaluate its immunogenicity using the hemagglutination inhibition assay, ELISA, and assess its efficacy in animals. We demonstrate the higher immunogenicity of the mRNA vaccine candidate compared to the inactivated split influenza vaccine and its enhanced ability to generate a cross-specific humoral immune response. These findings highlight the potential mRNA technology in overcoming current limitations of influenza vaccines and hold promise for ensuring greater efficacy in preventing seasonal influenza outbreaks.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Both vaccines showed detected immunogenicity using the HAI method. This method is the gold standard for assessing the immunogenicity of influenza vaccines and the efficacy of immunity against novel virus variants ( 29 ).…”

Section: Discussionmentioning

confidence: 99%

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Mazunina,

Gushchin,

Kleymenov

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Immunogenicity of prepared mRNAs were investigated in mice using HAI assay, as described previously [23]. Initially, we tested the immunogenicity of H1 and H3 HA-encoding mRNAs separately (Supplementary Figure S1).…”

Section: Immunogenicity Of Two Doses Of the Multivalent Ha-mrna Vaccinementioning

confidence: 99%

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Mazunina,

Gushchin,

Kleymenov

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Seasonal influenza remains a serious global health problem, leading to high mortality rates among the elderly and individuals with comorbidities. It also imposes a substantial economic burden through increased absenteeism during periods of active pathogen circulation. Vaccination is generally accepted as the most effective strategy for influenza prevention. As both influenza A and B viruses circulate and cause seasonal epidemics, vaccines need to include multiple antigens derived from different viral subtypes. While current influenza vaccines are effective, they still have limitations, including narrow specificity for certain serological variants, which may result in a mismatch between vaccine antigens and circulating strains. Additionally, the rapid variability of the virus poses challenges in providing extended protection beyond a single season. Therefore, mRNA technology is particularly promising for influenza prevention, as it enables the rapid development of multivalent vaccines and allows for quick updates of their antigenic composition. mRNA vaccines have already proven successful in preventing COVID-19 by eliciting rapid cellular and humoral immune responses. In this study, we present the development of a trivalent mRNA vaccine candidates, evaluate its immunogenicity using the hemagglutination inhibition assay, and assess its efficacy in animals. We demonstrate the higher immunogenicity of the mRNA vaccine candidates compared to the inactivated split influenza vaccine and its enhanced ability to generate a cross-specific humoral immune response. These findings highlight the potential mRNA technology in overcoming current limitations of influenza vaccines and hold promise for ensuring greater efficacy in preventing seasonal influenza outbreaks.

show abstract

Spread of Pathogens Causing Respiratory Viral Diseases Before and During CoVID-19 Pandemic in Kazakhstan

КЛИВЛЕЕВА¹,

Lukmanova²,

Glebova³

et al. 2023

Indian J Microbiol

View full text Add to dashboard Cite

swabs were collected from children under 17 years of age (60.75%). In 702 samples (9.85%) pathogens of respiratory infections of non-influenza etiology were detected, including adenovirus, bocavirus, coronavirus, metapneumovirus, paramyxovirus types I-IV, respiratory syncytial virus, and rhinovirus. At the same time, both before and during the COVID-19 pandemic, different influenza virus variants cocirculation (A/H1N1, A/H3N2, and type B) were discovered, with a predominance of viruses with the antigenic formula A/H1N1. The results of the study indicate the need for continuous monitoring of the viral pathogens spread, which will expand the existing knowledge of the viral etiology of respiratory diseases and highlight the importance of viruses in the respiratory infections occurrence.

show abstract

Peculiarities of the influenza and ARVI viruses circulation during epidemic season 2019–2020 in some regions of Russia

Cited by 21 publications

References 16 publications

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Spread of Pathogens Causing Respiratory Viral Diseases Before and During CoVID-19 Pandemic in Kazakhstan

Contact Info

Product

Resources

About